The Food and Drug Administration (FDA) has granted Priority Review status for the cancer drug Avastin (bevacizumab) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. Avastin is already approved to treat specific types of colorectal, lung, kidney, and brain cancers. Avastin was also granted priority review for the treatment of cervical cancer. The Priority Review status is based on data from the Phase 3 AURELIA trial, a multicenter, randomized, open-label study in 361 women with platinum-resistant recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer who have received no more than two anticancer regimens prior to ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.